Skip to main content
Top
Published in: Alzheimer's Research & Therapy 1/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | Research

Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI

Authors: Paula M. Petrone, Adrià Casamitjana, Carles Falcon, Miquel Artigues, Grégory Operto, Raffaele Cacciaglia, José Luis Molinuevo, Verónica Vilaplana, Juan Domingo Gispert, for the Alzheimer’s Disease Neuroimaging Initiative

Published in: Alzheimer's Research & Therapy | Issue 1/2019

Login to get access

Abstract

Background

Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer’s disease (AD) pathophysiologic continuum constituting what has been established as “AD signature”. To what extent MRI can detect amyloid-related cerebral changes from structural MRI in cognitively unimpaired individuals is still an area open for exploration.

Method

Longitudinal 3D-T1 MRI scans were acquired from a subset of the ADNI cohort comprising 403 subjects: 79 controls (Ctrls), 50 preclinical AD (PreAD), and 274 MCI and dementia due to AD (MCI/AD). Amyloid CSF was used as gold-standard measure with established cutoffs (< 192 pg/mL) to establish diagnostic categories. Cognitively unimpaired individuals were defined as Ctrls if were amyloid negative and PreAD otherwise. The MCI/AD group was amyloid positive. Only subjects with the same diagnostic category at baseline and follow-up visits were considered for the study. Longitudinal morphometric analysis was performed using SPM12 to calculate Jacobian determinant maps. Statistical analysis was carried out on these Jacobian maps to identify structural changes that were significantly different between diagnostic categories. A machine learning classifier was applied on Jacobian determinant maps to predict the presence of abnormal amyloid levels in cognitively unimpaired individuals. The performance of this classifier was evaluated using receiver operating characteristic curve analysis and as a function of the follow-up time between MRI scans. We applied a cost function to assess the benefit of using this classifier in the triaging of individuals in a clinical trial-recruitment setting.

Results

The optimal follow-up time for classification of Ctrls vs PreAD was Δt > 2.5 years, and hence, only subjects within this temporal span are used for evaluation (15 Ctrls, 10 PreAD). The longitudinal voxel-based classifier achieved an AUC = 0.87 (95%CI 0.72–0.97). The brain regions that showed the highest discriminative power to detect amyloid abnormalities were the medial, inferior, and lateral temporal lobes; precuneus; caudate heads; basal forebrain; and lateral ventricles.

Conclusions

Our work supports that machine learning applied to longitudinal brain volumetric changes can be used to predict, with high precision, the presence of amyloid abnormalities in cognitively unimpaired subjects. Used as a triaging method to identify a fixed number of amyloid-positive individuals, this longitudinal voxel-wise classifier is expected to avoid 55% of unnecessary CSF and/or PET scans and reduce economic cost by 40%.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gregory S, et al. Research participants as collaborators: background, experience and policies from the PREVENT Dementia and EPAD programmes. Dementia. 2018;17(8):1045–54.CrossRef Gregory S, et al. Research participants as collaborators: background, experience and policies from the PREVENT Dementia and EPAD programmes. Dementia. 2018;17(8):1045–54.CrossRef
3.
go back to reference Dubois B, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer’s & Dementia. 2016;12.3:292–323.CrossRef Dubois B, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer’s & Dementia. 2016;12.3:292–323.CrossRef
4.
go back to reference Frisoni GB, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67.CrossRef Frisoni GB, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67.CrossRef
5.
go back to reference Dickerson BC, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiology of aging. 2001;22.5:747–54.CrossRef Dickerson BC, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiology of aging. 2001;22.5:747–54.CrossRef
6.
go back to reference Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270–9.CrossRef Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270–9.CrossRef
7.
go back to reference Fennema-Notestine C, et al. Structural MRI biomarkers for preclinical and mild Alzheimer’s disease. Hum Brain Mapp. 2009;30(10):3238–53.CrossRef Fennema-Notestine C, et al. Structural MRI biomarkers for preclinical and mild Alzheimer’s disease. Hum Brain Mapp. 2009;30(10):3238–53.CrossRef
8.
go back to reference Killiany RJ, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58(8):1188–96.CrossRef Killiany RJ, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58(8):1188–96.CrossRef
9.
go back to reference ten Kate M, et al. Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers Res Ther. 2018;101:112.CrossRef ten Kate M, et al. Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers Res Ther. 2018;101:112.CrossRef
10.
go back to reference Falcon C, et al. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer’s disease: a study of two independent datasets. NeuroImage. 2018;19:190–201.CrossRef Falcon C, et al. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer’s disease: a study of two independent datasets. NeuroImage. 2018;19:190–201.CrossRef
11.
go back to reference Dickerson BC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16):1395–402.CrossRef Dickerson BC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16):1395–402.CrossRef
12.
go back to reference Rathore S, et al. A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer’s disease and its prodromal stages. NeuroImage. 2017;155:530–48.CrossRef Rathore S, et al. A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer’s disease and its prodromal stages. NeuroImage. 2017;155:530–48.CrossRef
13.
go back to reference Casamitjana A, et al. MRI-based screening of preclinical Alzheimer’s disease for prevention clinical trials. J Alzheimers Dis. 2018;64(4):1099-112.CrossRef Casamitjana A, et al. MRI-based screening of preclinical Alzheimer’s disease for prevention clinical trials. J Alzheimers Dis. 2018;64(4):1099-112.CrossRef
14.
go back to reference ten Kate M, et al. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimers Res Ther. 2018;101:100.CrossRef ten Kate M, et al. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimers Res Ther. 2018;101:100.CrossRef
16.
go back to reference Jack CR, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dementia. 2018;14.4:535–62.CrossRef Jack CR, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dementia. 2018;14.4:535–62.CrossRef
17.
go back to reference Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403–13.CrossRef Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403–13.CrossRef
21.
go back to reference Dukart J, et al. Age correction in dementia–matching to a healthy brain. PLoS One. 2011;6(7):e22193.CrossRef Dukart J, et al. Age correction in dementia–matching to a healthy brain. PLoS One. 2011;6(7):e22193.CrossRef
22.
go back to reference Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics. 2007;23(19):2507–17.CrossRef Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics. 2007;23(19):2507–17.CrossRef
23.
go back to reference Le Cessie S, Van Houwelingen JC. Ridge estimators in logistic regression. Appl Stat. 1992;41(1):191–201.CrossRef Le Cessie S, Van Houwelingen JC. Ridge estimators in logistic regression. Appl Stat. 1992;41(1):191–201.CrossRef
24.
go back to reference Varoquaux G, et al. Assessing and tuning brain decoders: cross-validation, caveats, and guidelines. NeuroImage. 2017;145:166–79.CrossRef Varoquaux G, et al. Assessing and tuning brain decoders: cross-validation, caveats, and guidelines. NeuroImage. 2017;145:166–79.CrossRef
25.
go back to reference Pedregosa F, et al. Scikit-learn: machine learning in Python. J Machine Learn Res. 2011;12(Oct):2825–30. Pedregosa F, et al. Scikit-learn: machine learning in Python. J Machine Learn Res. 2011;12(Oct):2825–30.
26.
go back to reference Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313.19:1924–38.CrossRef Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313.19:1924–38.CrossRef
27.
go back to reference Neurol S. Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol. 2013;33(4):386–416.CrossRef Neurol S. Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol. 2013;33(4):386–416.CrossRef
28.
go back to reference Ansart M, et al. Prediction of amyloidosis from neuropsychological and MRI data for cost effective inclusion of pre-symptomatic subjects in clinical trials. Deep learning in medical image analysis and multimodal learning for clinical decision support. Cham: Springer; 2017. p. 357–64. Ansart M, et al. Prediction of amyloidosis from neuropsychological and MRI data for cost effective inclusion of pre-symptomatic subjects in clinical trials. Deep learning in medical image analysis and multimodal learning for clinical decision support. Cham: Springer; 2017. p. 357–64.
29.
go back to reference Molinuevo JL, et al. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer’s disease. Alzheimers Dementia. 2016;2(2):82–92. Molinuevo JL, et al. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer’s disease. Alzheimers Dementia. 2016;2(2):82–92.
30.
go back to reference Fischl B, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33.3:341–55.CrossRef Fischl B, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33.3:341–55.CrossRef
31.
go back to reference Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95–113.CrossRef Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95–113.CrossRef
32.
go back to reference Evans AC, et al. 3D statistical neuroanatomical models from 305 MRI volumes Nuclear Science Symposium and Medical Imaging Conference, 1993. 1993 IEEE Conference Record. IEEE (New Jersey); 1993. Evans AC, et al. 3D statistical neuroanatomical models from 305 MRI volumes Nuclear Science Symposium and Medical Imaging Conference, 1993. 1993 IEEE Conference Record. IEEE (New Jersey); 1993.
33.
go back to reference Storandt M, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66:1476–81.CrossRef Storandt M, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66:1476–81.CrossRef
34.
go back to reference Fjell AM, et al. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex. 2010;20(9):2069–79.CrossRef Fjell AM, et al. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex. 2010;20(9):2069–79.CrossRef
35.
go back to reference Tosun D, et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010;31:1340–54.CrossRef Tosun D, et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010;31:1340–54.CrossRef
36.
go back to reference Becker JA, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032–42.CrossRef Becker JA, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032–42.CrossRef
37.
go back to reference Arenaza-Urquijo EM, et al. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-beta levels. J Alzheimers Dis. 2013;35(4):715–26.CrossRef Arenaza-Urquijo EM, et al. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-beta levels. J Alzheimers Dis. 2013;35(4):715–26.CrossRef
38.
go back to reference Falahati F, Westman E, Simmons A. Multivariate data analysis and machine learning in Alzheimer’s disease with a focus on structural magnetic resonance imaging. J Alzheimers Dis. 2014;41(3):685–708.CrossRef Falahati F, Westman E, Simmons A. Multivariate data analysis and machine learning in Alzheimer’s disease with a focus on structural magnetic resonance imaging. J Alzheimers Dis. 2014;41(3):685–708.CrossRef
39.
go back to reference Leow AD, et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage. 2006;31(2):627–40.CrossRef Leow AD, et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage. 2006;31(2):627–40.CrossRef
40.
go back to reference Hua X, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer’s disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43(3):458–69.CrossRef Hua X, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer’s disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43(3):458–69.CrossRef
41.
go back to reference Wolz R, et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer’s disease. PLoS One. 2011;6(10):e25446.CrossRef Wolz R, et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer’s disease. PLoS One. 2011;6(10):e25446.CrossRef
42.
go back to reference Plant C, et al. Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer’s disease. Neuroimage. 2010;50(1):162–74.CrossRef Plant C, et al. Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer’s disease. Neuroimage. 2010;50(1):162–74.CrossRef
43.
go back to reference Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics. 2007;19:2507–17.CrossRef Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics. 2007;19:2507–17.CrossRef
Metadata
Title
Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI
Authors
Paula M. Petrone
Adrià Casamitjana
Carles Falcon
Miquel Artigues
Grégory Operto
Raffaele Cacciaglia
José Luis Molinuevo
Verónica Vilaplana
Juan Domingo Gispert
for the Alzheimer’s Disease Neuroimaging Initiative
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2019
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-019-0526-8

Other articles of this Issue 1/2019

Alzheimer's Research & Therapy 1/2019 Go to the issue